Nico Slegers

As the demand for our #CellTherapy increases, it is crucial to have a robust onboarding and training framework that ensures new employees thrive in a highly regulated environment.   In just three years, we have welcomed 700+ professionals across our two state-of-the-art manufacturing sites in Ghent to expand capacity and meet patients’ needs.   Voka Oost-Vlaanderen invited our Associate Director Head of Training & Capabilities, Sofie Vercruysse, and Senior Director of HR Europe, An Moernaut, to discuss how structured training and a people-centric approach ensure operational excellence.   Read more: https://lnkd.in/e-f8w9Cm   #WeAreLegend #BiotechManufacturing #BiotechCareers #CellTherapy #CART

180

3 Comments

Today, we announced the expansion of our ADC pipeline — and our collaboration with Synaffix BV — to develop two novel bispecific candidates. SOT112 and SOT113 are our first investigational bispecific ADCs for #cancer treatment. These candidates offer exciting potential for treating solid tumors, with SOT112 targeting multiple cancer types and SOT113 focusing on precision treatment for #prostatecancer. Read more in today’s release: https://lnkd.in/eH6h5J6j #DrugDiscovery #ADC #Biotechnology #jsmePPF

88

Novel excipients play a pivotal role in enabling the precision and performance of today’s nanomedicines. In our latest whitepaper, Dirk-Jan van Zoelen, Business Unit Director Drug Substance at Ardena, shares insights from two real-world case studies involving phospholipid-based excipients, developed for a thermosensitive liposome and a targeted oncology therapy. The paper outlines the path from complex synthesis through late-stage development and GMP manufacturing, highlighting how integrated teams and phase-appropriate strategies are key to success. Read the full whitepaper below, and find more information about our nanomedicine expertise at https://lnkd.in/diMC-jE2 #Nanomedicine #Excipients #DrugDevelopment #CDMO #PharmaceuticalSciences #Ardena

74

What’s the difference between a CMO and a CDMO? 💬 A CMO (Contract Manufacturing Organization) provides manufacturing services. A CDMO (Contract Development and Manufacturing Organization) goes further: partnering with clients from early development to commercial supply. At AGC Pharma Chemicals, we work as a CDMO because we believe in collaboration, not just production. From process development and scale-up to regulatory support and HPAPI manufacturing, we build solutions that adapt to each molecule’s journey. How do you define the value of a true CDMO partner? #agc #CDMO #PharmaManufacturing #API #HPAPI #CDMO #smallmolecule #chemicals

64

4 Comments

Syngene partners with Orocidin A/S to deliver a clinically compliant antimicrobial peptide for advanced gum disease   Pharmaceutical Technology highlights Syngene’s collaboration with Orocidin A/S in their mission to combat aggressive periodontitis through the development of a novel antimicrobial peptide.   The challenge: QR-01’s complex chemistry posed significant hurdles in synthesis and purification, including aggregation, oxidation sensitivity, and poor solubility.   Syngene’s solution: 🔹 Low-loading resin to minimize aggregation during SPPS 🔹 Optimized cleavage chemistry for cleaner crude output 🔹 Specialized solvent mix to enhance solubility 🔹 Tailored single-step HPLC purification achieving >99% purity with just 0.6% total impurities   Read more to discover how this global collaboration sets a new benchmark in high-purity peptide production and exemplifies Syngene’s ability to translate complex science into clinical success. https://lnkd.in/gU9q72Wk   #Syngene #OrocidinAS #BiotechInnovation #PeptideSynthesis #GMPManufacturing #PharmaPartnerships #LifeSciences #ClinicalDevelopment

67

𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀: 𝗔𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝗮𝗹 𝗟𝗶𝗳𝗲𝗰𝘆𝗰𝗹𝗲 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 (𝗔𝗟𝗖𝗠) Analytical Quality by Design (AQbD)might seem less mature for RNA therapeutics than other pharmaceuticals but for us, it is essential for continued development of high-quality RNA therapeutics. Our latest whitepaper by Niels Delamotte, Director Analytical Development, about analytical lifecycle management is now available for free download! This whitepaper dives into: 1️⃣How Quality by Design (QbD) principles are used during analytical development. 2️⃣The role of ICH Q14 and USP <1220> in establishing an Analytical Lifecycle program. 3️⃣How the Analytical Target Profile (ATP) forms the basis for analytical development. 4️⃣The phase-appropriate transition of methods from development into validation - aligned with the product development stage. Don't miss the opportunity to stay ahead in the field of RNA therapeutics and analytical innovation! Download the whitepaper now.  👉🏻https://lnkd.in/etyZt_2E

51